RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) who are candidates for systemic ...
AbbVie (NYSE: ABBV) will announce its third-quarter 2026 financial results on Friday, October 30, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call ...
AbbVie presents 60 abstracts and presentations from a robust portfolio spanning across alopecia areata, atopic dermatitis, hidradenitis suppurativa, non-segmental vitiligo, psoriasis and ...
Phase 2 data in adults with atopic dermatitis showed that all three zumilokibart dose regimens met the primary endpoint, with significantly greater improvements in Eczema Area and Severity ...
Detailed findings, to be presented in a short oral presentation, demonstrated an approximately 11- to 12-day half-life and dose-proportional increases in plasma exposure, supporting evaluation of ABBV ...
NORTH CHICAGO, Ill., Sept. 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) is investing in its artificial intelligence (AI) infrastructure through a new partnership with Valkai, a life sciences AI ...
JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...
RINVOQ is now approved in the European Union for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older who have responded ...
On behalf of AbbVie, Perry Siatis, Executive Vice President, General Counsel and Secretary, testified in front of the U.S. Trade Representative (USTR) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results